Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) insider Markus Puhlmann acquired 35,000 shares of the business’s stock in a transaction that occurred on Thursday, November 12th. The shares were purchased at an average price of $0.84 per share, with a total value of $29,400.00. Following the completion of the transaction, the insider owned 178,542 shares of the company’s stock, valued at $149,975.28. The trade was a 24.38% increase in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Markus Puhlmann also recently made the following trade(s):
- On Wednesday, November 11th, Markus Puhlmann bought 6,000 shares of Perspective Therapeutics stock. The shares were purchased at an average cost of $0.83 per share, for a total transaction of $4,980.00.
Perspective Therapeutics Price Performance
Shares of CATX stock opened at $0.94 on Monday. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average is $2.11 and its two-hundred day moving average is $3.44. Perspective Therapeutics, Inc. has a 12 month low of $0.78 and a 12 month high of $6.16.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.06 million. Equities research analysts anticipate that Perspective Therapeutics, Inc. will post -1.01 EPS for the current fiscal year.
Key Perspective Therapeutics News
These are some of the CATX news items that stood out recently:
- Positive Sentiment: BMO Capital gave CATX a Buy rating, adding a bullish analyst view. BMO Capital rating
- Neutral Sentiment: Brookline Capital Markets made slightly different revisions to its earnings forecasts: it raised its Q4 2026 estimate to a loss of $0.25 per share from $0.26, but lowered its full-year estimate to a loss of $1.00 from $0.99. Perspective Therapeutics analyst estimates
- Negative Sentiment: The company’s latest reported quarter missed expectations: its loss of $0.27 per share was wider than the $0.24 consensus estimate, while revenue of $0.02 million fell short of the $0.06 million forecast. This weak operating performance may weigh on sentiment. CATX earnings information
Analyst Ratings Changes
CATX has been the subject of a number of research analyst reports. William Blair assumed coverage on shares of Perspective Therapeutics in a research report on Friday, September 18th. They set an “outperform” rating for the company. Piper Sandler dropped their target price on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a report on Tuesday, August 11th. Royal Bank Of Canada lowered Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and cut their target price for the company from $14.00 to $4.00 in a research report on Monday, October 26th. Wedbush restated an “outperform” rating and set a $7.00 price target (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. Finally, BMO Capital Markets restated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Nine research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.
Check Out Our Latest Stock Report on Perspective Therapeutics
Hedge Funds Weigh In On Perspective Therapeutics
Several institutional investors have recently bought and sold shares of the company. Provenance Wealth Advisors LLC acquired a new stake in shares of Perspective Therapeutics during the third quarter worth about $44,000. Auctus Advisors LLC boosted its stake in shares of Perspective Therapeutics by 83.6% in the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock valued at $103,000 after purchasing an additional 17,015 shares during the period. Russell Investments Group Ltd. boosted its stake in shares of Perspective Therapeutics by 53.1% in the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after purchasing an additional 21,150 shares during the period. Taylor & Morgan Wealth Management LLC boosted its stake in shares of Perspective Therapeutics by 127.6% in the second quarter. Taylor & Morgan Wealth Management LLC now owns 66,000 shares of the company’s stock valued at $225,000 after purchasing an additional 37,000 shares during the period. Finally, Quantinno Capital Management LP acquired a new position in shares of Perspective Therapeutics in the first quarter valued at approximately $273,000. 54.66% of the stock is owned by institutional investors and hedge funds.
Perspective Therapeutics Company Profile
Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.
Recommended Stories
- Five stocks we like better than Perspective Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
